DE69434977D1 - HIV Protease Inhibitoren - Google Patents

HIV Protease Inhibitoren

Info

Publication number
DE69434977D1
DE69434977D1 DE69434977T DE69434977T DE69434977D1 DE 69434977 D1 DE69434977 D1 DE 69434977D1 DE 69434977 T DE69434977 T DE 69434977T DE 69434977 T DE69434977 T DE 69434977T DE 69434977 D1 DE69434977 D1 DE 69434977D1
Authority
DE
Germany
Prior art keywords
protease inhibitors
hiv protease
hiv
inhibitors
protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434977T
Other languages
English (en)
Other versions
DE69434977T2 (de
Inventor
Bruce A Dressman
James E Fritz
Marlys Hammond
William J Hornback
Stephen W Kaldor
Vincent J Kalish
John E Munroe
Siegfried Heinz Reich
John H Tatlock
Timothy A Shepherd
Michael J Rodriguez
Louis N Jungheim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agouron Pharmaceuticals LLC
Original Assignee
Agouron Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals LLC filed Critical Agouron Pharmaceuticals LLC
Application granted granted Critical
Publication of DE69434977D1 publication Critical patent/DE69434977D1/de
Publication of DE69434977T2 publication Critical patent/DE69434977T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/62—Isoquinoline or hydrogenated isoquinoline ring systems
DE69434977T 1993-10-07 1994-10-07 HIV Protease Inhibitoren Expired - Lifetime DE69434977T2 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13354393A 1993-10-07 1993-10-07
US13369693A 1993-10-07 1993-10-07
US133543 1993-10-07
US133696 1993-10-07
US190764 1994-02-02
US08/190,764 US5484926A (en) 1993-10-07 1994-02-02 HIV protease inhibitors

Publications (2)

Publication Number Publication Date
DE69434977D1 true DE69434977D1 (de) 2007-07-05
DE69434977T2 DE69434977T2 (de) 2008-03-13

Family

ID=27384442

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69431193T Expired - Lifetime DE69431193T2 (de) 1993-10-07 1994-10-07 Hiv - protease inhibitoren
DE69434977T Expired - Lifetime DE69434977T2 (de) 1993-10-07 1994-10-07 HIV Protease Inhibitoren
DE69434214T Expired - Lifetime DE69434214T2 (de) 1993-10-07 1994-10-07 HIV protease inhibitoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69431193T Expired - Lifetime DE69431193T2 (de) 1993-10-07 1994-10-07 Hiv - protease inhibitoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69434214T Expired - Lifetime DE69434214T2 (de) 1993-10-07 1994-10-07 HIV protease inhibitoren

Country Status (36)

Country Link
US (14) US5484926A (de)
EP (3) EP0722439B1 (de)
JP (2) JP2951724B2 (de)
KR (1) KR100190517B1 (de)
CN (2) CN1195737C (de)
AP (1) AP600A (de)
AT (3) ATE222240T1 (de)
AU (1) AU694746B2 (de)
BG (1) BG62567B1 (de)
BR (1) BR9407782A (de)
CA (2) CA2173328C (de)
CZ (1) CZ290417B6 (de)
DE (3) DE69431193T2 (de)
DK (2) DK0722439T3 (de)
EE (1) EE05399B1 (de)
ES (3) ES2236849T3 (de)
FI (1) FI114794B (de)
GE (2) GEP20002209B (de)
HK (3) HK1013650A1 (de)
HU (2) HU227885B1 (de)
MD (1) MD1507G2 (de)
MY (1) MY138860A (de)
NO (1) NO307050B1 (de)
NZ (2) NZ275633A (de)
OA (1) OA10718A (de)
PL (1) PL185647B1 (de)
PT (2) PT722439E (de)
RO (1) RO119363B1 (de)
RU (1) RU2139280C1 (de)
SI (2) SI0722439T1 (de)
SK (2) SK284116B6 (de)
TJ (1) TJ339B (de)
TW (1) TW432049B (de)
UA (1) UA56984C2 (de)
UY (1) UY23840A1 (de)
WO (1) WO1995009843A1 (de)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
USH1649H (en) * 1987-07-31 1997-05-06 Barrish; Joel C. HIV protease inhibitor combinations
US7141609B2 (en) 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
WO1994004492A1 (en) 1992-08-25 1994-03-03 G.D. Searle & Co. Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5514801A (en) 1992-12-29 1996-05-07 Monsanto Company Cyclic sulfone containing retroviral protease inhibitors
IL110255A (en) * 1993-07-16 1998-12-06 Merck & Co Inc Creation and resolution of 2 tert-butylcarboxamidopiprazine
US5480887A (en) * 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
DE69426655T2 (de) * 1994-02-02 2001-06-13 Lilly Co Eli Hiv-protease inhibitoren und zwischenprodukte
US5461154A (en) * 1994-02-02 1995-10-24 Eli Lilly And Company Intermediate and process for making
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US20030207813A1 (en) * 1996-12-09 2003-11-06 G.D. Searle Retroviral protease inhibitor combinations
US5831117A (en) * 1995-01-20 1998-11-03 G. D. Searle & Co. Method of preparing retroviral protease inhibitor intermediates
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
EP0984000B1 (de) * 1995-09-26 2008-12-03 Japan Tabacco Inc. Verfahren zur herstellung von amidderivaten und ihren zwischenverbindungen
ATE288891T1 (de) 1995-09-26 2005-02-15 Japan Tobacco Inc Verfahren zur herstellung von amid-derivaten und ihren zwischenverbindungen
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
ES2332271T3 (es) * 1996-06-05 2010-02-01 Kabushiki Kaisha Sega Doing Business As Sega Corporation Dispositivo de procesamiento de graficos, metodo de procesamiento de graficos, maquina de juegos y medio de almacenamiento.
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
UA67727C2 (uk) * 1996-09-05 2004-07-15 Агурон Фармасевтікелс, Інк. Проміжні сполуки для одержання інгібіторів віл-протеази і способи одержання інгібіторів віл-протеази
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
DE19704885C1 (de) * 1997-02-11 1998-06-10 Clariant Gmbh Verfahren zur Herstellung von 3-Hydroxy-2-methylbenzoesäure und 3-Acetoxy-2-methylbenzoesäure
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
HRP980112A2 (en) * 1997-03-13 1998-12-31 Agouron Pharma Hiv protease inhibitors
US6130348A (en) 1997-04-10 2000-10-10 Hoffmann-La Roche Inc. Process for a phenylthiobutyl-isoquinoline and intermediates therefor
ATE234288T1 (de) * 1997-04-10 2003-03-15 Hoffmann La Roche Verfahren zur herstellung eines buthylthuio- isochinolinderivates und zwischenprodukte dafür
US6123694A (en) * 1997-05-09 2000-09-26 Paragon Trade Brands Disposable absorbent article with unitary leg gathers
DE19730602A1 (de) * 1997-07-17 1999-01-21 Clariant Gmbh 3-Acetoxy-2-methylbenzoesäurechlorid und ein Verfahren zu seiner Herstellung
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
IN188157B (de) 1998-01-16 2002-08-24 Japan Tobacco Inc
US6124500A (en) * 1998-03-09 2000-09-26 Rohm And Haas Company Process for synthesizing benzoic acids
FR2776292B1 (fr) * 1998-03-20 2004-09-10 Oncopharm Cephalotaxanes porteurs de chaine laterale et leur procede de synthese
AU6852998A (en) * 1998-04-16 1999-11-08 Nagase & Company, Ltd. Process for preparing chloro alcohol derivatives and intermediates
EP1086076B1 (de) 1998-06-19 2004-12-22 Vertex Pharmaceuticals Incorporated Sulfonamide als aspartyl-protease-inhibitoren
EP1095022A1 (de) * 1998-07-08 2001-05-02 G.D. Searle & Co. Inhibitoren von retoviraler protease
US6107511A (en) * 1998-07-29 2000-08-22 Kaneka Corporation Process for the purification or isolation of (2S,3R)-1-halo-2-hydroxy-3-(protected amino)4-phenylthiobutanes or optical antipodes thereof
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7635690B2 (en) * 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
TNSN00027A1 (fr) 1999-02-12 2005-11-10 Vertex Pharma Inhibiteurs de l'aspartyle protease
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
JP2002539246A (ja) 1999-03-22 2002-11-19 イミュジェン ファーマシューティカルズ インコーポレイティッド 免疫疾患の治療
AU6109500A (en) * 1999-07-20 2001-02-05 Merck & Co., Inc. Alpha-hydroxy-gamma-(((carbocyclic-or heterocyclic-substituted)amino)carbonyl)alkanamide derivatives and uses thereof
US6589962B1 (en) 1999-07-20 2003-07-08 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
KR100339831B1 (ko) * 1999-08-18 2002-06-07 김태성 신규의 에틸 아지리딘 유도체 및 그 제조방법
US6403799B1 (en) 1999-10-21 2002-06-11 Agouron Pharmaceuticals, Inc. Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors
JP2003514910A (ja) 1999-11-24 2003-04-22 メルク エンド カムパニー インコーポレーテッド Ｈｉｖプロテアーゼ阻害剤としてのガンマ−ヒドロキシ−２−（フルオロアルキルアミノカルボニル）−１−ピペラジンペンタンアミド類
CA2395987C (en) 2000-01-19 2009-12-22 Abbott Laboratories Improved pharmaceutical formulations
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US7119085B2 (en) * 2000-03-23 2006-10-10 Elan Pharmaceuticals, Inc. Methods to treat alzheimer's disease
US6448245B1 (en) 2000-05-04 2002-09-10 The United States Of America As Represented By The Department Of Health And Human Services Methods of and compounds for inhibiting calpains
US20020198207A1 (en) * 2000-05-18 2002-12-26 Kath John Charles Novel Hexanoic acid derivatives
CA2410680A1 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
EP1666452A2 (de) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Verbindungen zur Behandlung der Alzheimerischen Krankheit
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
US7425537B2 (en) * 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
WO2002026224A2 (en) * 2000-09-28 2002-04-04 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
WO2002026728A2 (en) * 2000-09-28 2002-04-04 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
IT1318986B1 (it) * 2000-10-09 2003-09-19 Archimica S P A Ora Clariant L Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
DK1358458T3 (da) * 2000-10-19 2012-06-18 Target Discovery Inc Massedefektmærkning til bestemmelse af oligomersekvenser
JPWO2002064553A1 (ja) * 2001-02-14 2004-06-10 呉羽化学工業株式会社 ハロゲノアルコール誘導体の製造方法
HN2002000136A (es) 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
JP2005500319A (ja) 2001-06-27 2005-01-06 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病の治療に有用なβ−ヒドロキシアミン誘導体
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
US20030191121A1 (en) * 2001-08-09 2003-10-09 Miller Ross A. Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
US20030068655A1 (en) * 2001-09-12 2003-04-10 Protiveris, Inc. Microcantilever apparatus and methods for detection of enzymes
US6696494B2 (en) 2001-10-22 2004-02-24 Enanta Pharmaceuticals, Inc. α-hydroxyarylbutanamine inhibitors of aspartyl protease
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
AU2003214226A1 (en) * 2002-03-18 2003-10-08 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
DE10212885A1 (de) * 2002-03-22 2003-10-02 Bayer Ag Verfahren zur Herstellung von 3-Hydroxy-2-methylbenzoesäure
EP1371626A3 (de) * 2002-06-13 2004-07-21 Bayer Chemicals AG Verfahren zur Herstellung von 3-Alkoxy-2-methylbenzoesäuren
DE10226219A1 (de) * 2002-06-13 2004-01-08 Bayer Ag Verfahren zur Herstellung von 3-Acyloxy-2-methylbenzoesäuren
CA2393720C (en) 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
ES2259400T3 (es) * 2002-08-21 2006-10-01 Lanxess Deutschland Gmbh Compuestos quirales de difosforo y sus complejos con metales de transicion.
NZ542072A (en) 2003-02-13 2007-11-30 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
WO2004099129A2 (en) * 2003-05-08 2004-11-18 Pfizer Inc. Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same
JP4731320B2 (ja) * 2003-07-15 2011-07-20 アリジェン製薬株式会社 抗コロナウイルス剤
US7211588B2 (en) * 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
DK1778251T3 (da) 2004-07-27 2011-07-18 Gilead Sciences Inc Nukleosidphosphatkonjugater som anti-HIV-midler
US8367832B2 (en) * 2004-08-23 2013-02-05 Mylan Laboratories Limited Crystalline forms of Nelfinavir mesylate
ATE540675T1 (de) 2005-04-01 2012-01-15 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
EP1910317B1 (de) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino-verbundene verbindungen
EP1910274B1 (de) 2005-07-20 2012-08-08 Eli Lilly And Company Phenylverbindungen
EP1976377A4 (de) 2006-01-25 2010-06-23 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
CN101374414A (zh) 2006-01-25 2009-02-25 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
US20090176885A1 (en) 2006-02-02 2009-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP4788958B2 (ja) * 2006-02-28 2011-10-05 東亞合成株式会社 抗ウイルス性ペプチドおよびその利用
JP4831410B2 (ja) * 2006-02-28 2011-12-07 東亞合成株式会社 抗ウイルス性ペプチドおよび抗ウイルス剤
US8779144B2 (en) * 2006-03-16 2014-07-15 Evotec (Us) Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
WO2008041087A1 (en) * 2006-10-06 2008-04-10 Aurobindo Pharma Limited An improved process for preparation of amorphous nelfinavir mesylate
WO2008112289A2 (en) 2007-03-12 2008-09-18 Nektar Therapeutics Oligomer-protease inhibitor conjugates
WO2009006203A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
SG182229A1 (en) * 2007-06-29 2012-07-30 Gilead Sciences Inc Therapeutic compositions and the use thereof
US20110105477A1 (en) * 2007-09-14 2011-05-05 The Regents Of The University Of Michigan Compositions and methods relating to hiv protease inhibition
WO2009042093A1 (en) * 2007-09-25 2009-04-02 Merck & Co., Inc. Hiv protease inhibitors
US9095620B2 (en) * 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
CN102976928B (zh) 2008-03-13 2014-09-17 维尔斯达医疗公司 用于降低尿酸的化合物
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
PL2364314T3 (pl) 2008-12-09 2014-08-29 Gilead Sciences Inc Modulatory receptorów Toll-podobnych
BRPI0923217A2 (pt) * 2008-12-11 2017-05-23 Glaxosmithkline Llc processos para a preparação de um composto de piridona, e para a preparação de uma forma cristalina, composto, sal ou um hidrato deste, forma cristalina de um sal de sódio ou um hidrato deste, e, composição farmacêutica.
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
AU2009329867B2 (en) 2008-12-23 2015-01-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
NZ617066A (en) * 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
CA2762582A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2010144869A2 (en) 2009-06-12 2010-12-16 Nektar Therapeutics Protease inhibitors
JP6093180B2 (ja) * 2009-12-10 2017-03-08 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク ヒストンアセチルトランスフェラーゼ活性化剤及びその使用
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
DE102010004957A1 (de) 2010-01-14 2011-07-21 Universitätsklinikum Jena, 07743 Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
AU2011235044A1 (en) 2010-03-31 2012-11-22 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
US9079834B2 (en) 2010-10-28 2015-07-14 Merck Canada Inc. HIV protease inhibitors
EP2771332B1 (de) 2011-10-26 2016-06-29 Merck Canada Inc. Thiophen- und Thiazol-Sulfonamid-Derivate als HIV Protease Inhibitoren zur Behandlung von AIDS
RU2015113091A (ru) 2012-09-11 2016-11-10 Мерк Шарп И Доум Корп. Ингибиторы протеазы вич
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
RU2505286C1 (ru) * 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
RU2543322C1 (ru) * 2013-09-19 2015-02-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
WO2015095276A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Hiv protease inhibitors
US9737545B2 (en) 2013-12-19 2017-08-22 Merck Sharp & Dohme Corp. HIV protease inhibitors
WO2015134366A1 (en) 2014-03-06 2015-09-11 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2015138220A1 (en) 2014-03-10 2015-09-17 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
AU2015287773B2 (en) 2014-07-11 2018-03-29 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
US9738664B2 (en) 2014-10-29 2017-08-22 Wisconsin Alumni Research Foundation Boronic acid inhibitors of HIV protease
MA42818A (fr) 2015-09-15 2018-07-25 Gilead Sciences Inc Modulateurs de récepteurs de type toll pour le traitement du vih
US10539397B2 (en) 2017-04-12 2020-01-21 Wilcox Industries Corp. Modular underwater torpedo system
BR112020005489A2 (pt) 2017-09-22 2020-09-24 Jubilant Epipad Llc, composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer
MX2020003341A (es) 2017-10-18 2020-09-17 Jubilant Epipad LLC Compuestos de imidazo-piridina como inhibidores de pad.
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
CN111542523B (zh) 2017-11-24 2024-03-29 朱比连特埃皮斯科瑞有限责任公司 作为prmt5抑制剂的杂环化合物
AU2019234185A1 (en) 2018-03-13 2020-10-01 Jubilant Prodel LLC. Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
WO2021176369A1 (en) 2020-03-06 2021-09-10 Pfizer Inc. Methods of inhibiting sars-cov-2 replication and treating coronavirus disease 2019
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2448392A1 (fr) * 1979-02-12 1980-09-05 Vilbiss Toussaint De Dispositif automatique pour la projection de produits de revetement
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
IL91307A0 (en) * 1988-08-24 1990-03-19 Merck & Co Inc Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them
EP0361341A3 (de) * 1988-09-28 1991-07-03 Miles Inc. Therapeutika für AIDS auf der Basis von HIV-Protease-Inhibitoren
US5063208A (en) * 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
WO1991008221A1 (en) * 1989-12-04 1991-06-13 Wisconsin Alumni Research Foundation Peptide inhibitors of hiv protease
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
CA2056911C (en) * 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
IL100899A (en) * 1991-02-08 1997-06-10 Sankyo Co Beta-amino-alpha- hydroxycarboxylic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5235039A (en) * 1991-06-10 1993-08-10 Eli Lilly And Company Substrates for hiv protease
US5508407A (en) * 1991-07-10 1996-04-16 Eli Lilly And Company Retroviral protease inhibitors
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
US5220796A (en) 1991-07-15 1993-06-22 The Boc Group, Inc. Adsorption condensation solvent recovery system
DE4126482A1 (de) * 1991-08-10 1993-02-11 Bayer Ag (alpha)-trifluormethyl-substituierte, gesaettigt-bicyclische amine und verfahren zu deren herstellung
US5516784A (en) * 1991-08-13 1996-05-14 Schering Corporation Anti-HIV (AIDS) agents
EP0534511A1 (de) * 1991-08-16 1993-03-31 Merck & Co. Inc. HIV-Protease-Hemmer zur Behandlung von AIDS
US5256783A (en) 1991-09-18 1993-10-26 Hoffmann-La Roche Inc. Method for producing 2-isoquinoline compounds
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
WO1993013066A1 (en) * 1991-12-20 1993-07-08 Syntex (U.S.A.) Inc. Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors
EP0560268B1 (de) * 1992-03-13 1995-01-04 Bio-Mega/Boehringer Ingelheim Research Inc. Substituierte Pipecoline-Säurederivate als HIV-Protease-Hemmer
EP1148050A1 (de) * 1992-05-21 2001-10-24 Monsanto Company Retrovirale Proteaseinhibitoren
WO1994004492A1 (en) * 1992-08-25 1994-03-03 G.D. Searle & Co. Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
DE69329544T2 (de) 1992-12-22 2001-05-31 Lilly Co Eli HIV Protease hemmende Verbindungen
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
MX9308025A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
US5733906A (en) * 1993-10-12 1998-03-31 Eli Lilly And Company Inhibitors of HIV Protease useful for the treatment of Aids
MX9308016A (es) 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
US5554653A (en) * 1992-12-22 1996-09-10 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
US5491166A (en) * 1992-12-22 1996-02-13 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
US5434265A (en) * 1992-12-22 1995-07-18 Eli Lilly And Company Inhibitors of HIV protease
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5475136A (en) * 1992-12-22 1995-12-12 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
US5480887A (en) * 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors

Also Published As

Publication number Publication date
MD1507G2 (ro) 2001-04-30
ATE362918T1 (de) 2007-06-15
MY138860A (en) 2009-08-28
HU226814B1 (en) 2009-11-30
SI0889036T1 (en) 2005-04-30
RU2139280C1 (ru) 1999-10-10
HU9600908D0 (en) 1996-05-28
HK1014950A1 (en) 1999-10-08
NO961382D0 (no) 1996-04-03
CZ100496A3 (en) 1996-09-11
US5837710A (en) 1998-11-17
DK0722439T3 (da) 2002-12-16
AU7967494A (en) 1995-05-01
EE9600091A (et) 1996-12-16
US20020077338A1 (en) 2002-06-20
EP0889036A1 (de) 1999-01-07
DE69434977T2 (de) 2008-03-13
EE05399B1 (et) 2011-04-15
US6271235B1 (en) 2001-08-07
US5827858A (en) 1998-10-27
SK43996A3 (en) 1997-01-08
CA2173328A1 (en) 1995-04-13
CN1131942A (zh) 1996-09-25
CN1262272A (zh) 2000-08-09
SI0722439T1 (en) 2002-10-31
ES2236849T3 (es) 2005-07-16
ATE286025T1 (de) 2005-01-15
HU0900219D0 (en) 2009-06-29
JPH09501443A (ja) 1997-02-10
SK284115B6 (sk) 2004-09-08
CZ290417B6 (cs) 2002-07-17
DE69434214D1 (de) 2005-02-03
CA2173328C (en) 1999-08-31
BG62567B1 (bg) 2000-02-29
EP0722439A1 (de) 1996-07-24
EP0889036B1 (de) 2004-12-29
NZ275633A (en) 1998-03-25
PT889036E (pt) 2005-05-31
NO961382L (no) 1996-04-09
BG100455A (en) 1997-09-30
CA2268709C (en) 2008-03-25
PL185647B1 (pl) 2003-06-30
ATE222240T1 (de) 2002-08-15
NZ329626A (en) 1999-08-30
TJ339B (en) 2002-07-01
EP1340744A2 (de) 2003-09-03
HK1013650A1 (en) 1999-09-03
AU694746B2 (en) 1998-07-30
US20030216569A1 (en) 2003-11-20
JPH11310573A (ja) 1999-11-09
US5852043A (en) 1998-12-22
WO1995009843A1 (en) 1995-04-13
BR9407782A (pt) 1997-03-18
US5834467A (en) 1998-11-10
FI961449A (fi) 1996-05-29
EP0722439B1 (de) 2002-08-14
SK284116B6 (sk) 2004-09-08
US6525215B2 (en) 2003-02-25
US6162812A (en) 2000-12-19
CN1046269C (zh) 1999-11-10
US5827891A (en) 1998-10-27
DE69431193D1 (en) 2002-09-19
PT722439E (pt) 2002-12-31
DK0889036T3 (da) 2005-02-28
HK1056172A1 (en) 2004-02-06
ES2287387T3 (es) 2007-12-16
AP9600844A0 (en) 1996-07-31
FI961449A0 (fi) 1996-03-29
US5827859A (en) 1998-10-27
US5484926A (en) 1996-01-16
EP1340744A3 (de) 2003-12-03
HUT75652A (en) 1997-05-28
JP2951724B2 (ja) 1999-09-20
US5952343A (en) 1999-09-14
MD1507F2 (en) 2000-07-31
UY23840A1 (es) 1994-10-21
US5824688A (en) 1998-10-20
GEP20002209B (en) 2000-08-25
UA56984C2 (uk) 2003-06-16
JP3703647B2 (ja) 2005-10-05
CA2268709A1 (en) 1995-04-13
DE69434214T2 (de) 2005-06-02
HU227885B1 (en) 2012-05-29
FI114794B (fi) 2004-12-31
DE69431193T2 (de) 2002-12-12
AP600A (en) 1997-07-23
PL313871A1 (en) 1996-07-22
RO119363B1 (ro) 2004-08-30
EP1340744B1 (de) 2007-05-23
OA10718A (en) 2001-11-02
US6693199B2 (en) 2004-02-17
TW432049B (en) 2001-05-01
US5859002A (en) 1999-01-12
GEP20084497B (en) 2008-09-25
KR100190517B1 (en) 1999-06-01
NO307050B1 (no) 2000-01-31
ES2181725T3 (es) 2003-03-01
CN1195737C (zh) 2005-04-06

Similar Documents

Publication Publication Date Title
DE69434977D1 (de) HIV Protease Inhibitoren
NO932620D0 (no) Amindiol-proteaseinhibitorer
NO942064D0 (no) yminhibitorer
NO20006718D0 (no) Proteaseinhibitorer
FI935644A (fi) Retrovirusten proteaasi-inhibiittoreita
FI962073A0 (fi) HIV-proteaasin estäjän prodrug-muotoja
EP0443560A3 (en) Hiv protease inhibitors
MX9100121A (es) Inhibidores de proteasas asparticas
EP0594586A4 (en) Hiv protease inhibitors
DE69431454D1 (de) Amylase Inhibitoren
NO920023L (no) Hiv-proteaseinhibitorer
NO994415L (no) HIV proteaseinhibitorer
SG49247A1 (en) Hiv protease inhibitors
HU0900220D0 (en) Hiv protease inhibitors
ZA919721B (en) Hiv protease inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition